Lessons Learned In Immuno-Oncology From Former Roche Exec Dan Chen

In an audio interview from the recent ASCO-SITC meeting, Chen weighs in on comparisons of PD-1 and PD-L1 inhibitors, the IDO failures, biomarkers and his new work at the private biotech IGM Biosciences.

Daniel Chen, Chief Medical Officer, IGM Biosciences

Daniel Chen is in an ideal position to weigh in on the past, present and future of cancer immunotherapy.

From 2006 to 2018 he worked for Genentech and Roche serving as the global head of the cancer immunotherapy...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer